Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2

Molecular Cancer Therapeutics

Volumn 4, Issue 12, 2005, Pages 1936-1942

  Hong, Liu ^a   Piao, Ying ^b   Han, Yu ^a   Wang, Jun ^a   Zhang, Xiaoyin ^a   Du, Yulei ^a   Cao, Shanshan ^a   Qiao, Taidong ^a   Chen, Zhen ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; GENE PRODUCT; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; UNCLASSIFIED DRUG; VINCRISTINE; ZINC RIBBON DOMAIN CONTAINING PROTEIN 1;

ANALYSIS OF VARIANCE; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CONCENTRATION RESPONSE; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SENSITIVITY ANALYSIS; UPREGULATION; WESTERN BLOTTING; ZINC FINGER MOTIF;

APOPTOSIS; BASE SEQUENCE; DNA PRIMERS; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HL-60 CELLS; HUMANS; LEUKEMIA; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VERAPAMIL;

EID: 30344451993     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0182     Document Type: Article

References (38)

1. Lage H, Perlitz C, Abel R, et al. Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone. FEBS Lett 2001;503:179-84.
2. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-5.
3. Fan KC, Fan DM, Cheng LF, Li C. Expression of multidrug resistance-related markers in leukemia. Anticancer Res 2000;20:4809-14.
4. Kim WJ, Kakehi Y, Wu WJ, Fukumoto M, Yoshida O. Expression of multidrug resistance-related genes (mdrl, MRP, GST-π and DNA topoisomerase II) in urothelial cancers. Br J Urol 1996;78:361-8.
5. Lavie Y, Fiucci G, Liscovitch M. Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv Drug Deliv Rev 2001;49:317-23.
6. Fan D, Zhang X, Chen X, et al. Bird's-eye view on gastric cancer research of the past 25 years. J Gastroenterol Hepatol 2005;20:360-5.
7. Fan W, Wang Z, Kyzysztof F, Prange C, Lennon G. A new zinc ribbon gene (ZNRD1) is cloned from the human MHC class I region. Genomics 2000;63:139-41.
8. Chu TW, Capossela A, Coleman R, Goei VL, Nallur G, Gruen JR. Cloning of a new "finger" protein gene (ZNF173) within the class I region of the human MHC. Genomics 1995;29:229-39.
9. Qian X, Jeon C, Yoon H, Agarwal K, Weiss MA. Structure of a new nucleic-acid-binding motif in eukaryotic transcriptional elongation factor TFIIS. Nature 1993;365:277-9.
10. Zhao Y, You H, Liu F, et al. Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett 2002;185:211-8.
11. Hong L, Ning X, Shi Y, et al. Reversal of multidrug resistance of gastric cancer cells by downregulation of ZNRD1 with ZNRD1 siRNA. Br J Biomed Sci 2004;61:206-10.
12. Shi Y, Zhang Y, Zhao Y, et al. Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-gp. Cancer Biol Ther 2004;3:24-8.
13. 1 phase. Cancer Biol Ther 2005;4:61-5.
14. Hong L, Zhang Y, Han S, et al. Preparation and characterization of a novel monoclonal antibody specific to human ZNRD1 protein. Hybrid Hybridomics 2004;23:65-8.
15. Hong L, Zhang Y, Liu N, et al. Suppression of the cell proliferation in stomach cancer cells by the ZNRD1 gene. Biochem Biophys Res Commun 2004;321:611-6.
16. Shi Y, Zhai H, Wang X, et al. Multidrug-resistance-associated protein MGr1-Ag is identical to the human 37-kDa laminin receptor precursor. Cell Mol Life Sci 2002;59:1577-83.
17. Ghalia AA, Rabboh NA, Shalakani A, Seada L, Khalifa A. Estimation of glutathione S-transferase and its π isoenzyme in tumor tissues and sera of patients with ovarian cancer. Anticancer Res 2000;20:1229-35.
18. Guo C, Ding J, Yao L, et al. Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int J Cancer 2005;116:155-60.
19. 3 receptor gene by ZEB. Cell Growth Differ 2001;12:319-26.
20. Du J, Pan Y, Shi Y, et al. Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR. Int J Cancer 2005;113:213-20.
21. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res 2000;60:1645-53.
22. Mi Q, Cui B, Silva GL, et al. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype. Cancer Res 2001;61:4030-7.
23. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999;59:3944-8.
24. 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 2003;9: 650-6.
25. Naito M, Matsuba Y, Sato S, Hirata H, Takashi Tsuruo T. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin Cancer Res 2002;8:582-8.
26. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem 1992; 15:24995-5002.
27. Gaitanos TN, Buey RM, Díaz JF, et al. Peloruside A does not bind to the taxoid site on β-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res 2004;64:5063-7.
28. Cabot MC, Giuliano AE, Han TY, Liu Y. SDZ PSC 833, the Cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res 1999;59:880-5.
29. Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG. Transcriptional regulators of the human multidrug resistance 1 gene, recent views. Biochem Pharmacol 2002;64:943-8.
30. Potocnik U, Glavac MR, Golouh R, Glavac D. The role of P-glycoprotein (MDR1) polymorphisms and mutations in colorectal cancer. Pflugers Arch 2001;442:182-3.
31. Waxman DJ, Glutathione S. Role in alkylating agent resistance and possible target for modulation chemotherapy - a review. Cancer Res 1990;50:6449-54.
32. Ruiz-Gomez MJ, Souviron A, Martinez-Morillo M, Gil L. P-gp, glutathione and glutathione S-transferase increase in a colon carcinoma cell line by colchicines. J Physiol Biochem 2000;56:307-12.
33. Yu DS, Ma CP, Chang SY. Establishment and characterization of renal cell carcinoma cell lines with multidrug resistance. Urol Res 2000;28:86-92.
34. Sakamoto M, Kondo A, Kawasaki K, et al. Analysis of gene expression profiles associated with CDDP resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 2001;14:305-15.
35. Bader P, Fuchs J, Wenderoth M, Schweinitz D, Niethammer D, Beck JF. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with Adriamycin or CDDP. Anticancer Res 1998;18:3127-32.
36. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-88.
37. Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997;275: 983-6.
38. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-53.